SCHEMBL5743483

SCHEMBL5743483

C=Cc1ccc(S(=O)(=O)N2CCN(CC3(NC(=O)OCC)CCN(c4ccnc(CO)c4)CC3)C(=O)C2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35
F10 P00742 2/20 0.34
F13A1 P00488 2/20 0.33
TGM2 P21980 2/20 0.33
TGM1 P22735 2/20 0.33
POLB P06746 1/20 0.32
LMNA P02545 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
MAPK1 P28482 2/20 0.31
PTPN11 Q06124 1/20 0.31
TSHR P16473 1/20 0.31
TGM3 Q08188 1/20 0.31
PTGDR Q13258 3/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
MAPT P10636 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
PKM P14618 1/20 0.31
F2 P00734 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5741976 0.92 ATM (0.37) ATMNPSR1F10F13A1TGM2
Hydrochloric Acid SCHEMBL5742036 0.92 ATM (0.36) ATMNPSR1F10F13A1TGM2
SCHEMBL5740518 0.91 ATM (0.36) ATMNPSR1F10F13A1TGM2
SCHEMBL5740527 0.89 ATM (0.39) ATMNPSR1F10F13A1TGM2
SCHEMBL5741290 0.84 CYP1A2 (0.37) ATMNPSR1F10F13A1TGM2
SCHEMBL5742599 0.83 F10 (0.38) ATMNPSR1F10LMNAMAPK1
SCHEMBL5740189 0.83 SMN1; SMN2 (0.39) F10F13A1TGM2TGM1LMNA
Hydrochloric Acid SCHEMBL5742042 0.81 F13A1 (0.38) ATMF13A1TGM2TGM1POLB
SCHEMBL5855055 0.80 CYP2C9 (0.34) ATMNPSR1F13A1TGM2TGM1
SCHEMBL5742755 0.80 LSS (0.44) ATMNPSR1F10LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109200-B2 Carbamate derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-09-19 US disclosed
EP-1340753-B1 CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2006-01-11 EP disclosed
US-20040038986-A1 Carbamate derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-02-26 US disclosed
EP-1340753-A1 CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038986-A1 Carbamate derivatives, process for producing the same and use thereof CFH, F11, F2 ATM 2643/4885NPSR1 2429/4885F10 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.